OneAscent Financial Services LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 75.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,306 shares of the company's stock after purchasing an additional 4,010 shares during the period. OneAscent Financial Services LLC's holdings in Novo Nordisk A/S were worth $644,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of NVO. Strategic Investment Solutions Inc. IL grew its position in shares of Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after buying an additional 300 shares during the last quarter. Park Square Financial Group LLC purchased a new stake in Novo Nordisk A/S in the 4th quarter valued at approximately $29,000. Transce3nd LLC acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at about $33,000. North Capital Inc. purchased a new position in Novo Nordisk A/S during the 1st quarter worth approximately $27,000. Finally, Copeland Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares during the period. 11.54% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
NVO has been the topic of a number of research reports. BMO Capital Markets restated a "market perform" rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating for the company. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of "Hold" and an average target price of $112.00.
Check Out Our Latest Analysis on Novo Nordisk A/S
Novo Nordisk A/S Stock Performance
NYSE NVO opened at $64.96 on Tuesday. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $139.74. The company has a market capitalization of $290.05 billion, a PE ratio of 19.22, a P/E/G ratio of 1.24 and a beta of 0.64. The company has a fifty day moving average of $70.34 and a two-hundred day moving average of $74.21. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The company had revenue of $11.87 billion for the quarter. As a group, analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.
Novo Nordisk A/S Profile
(
Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Articles
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
